Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine

被引：30

作者：

Talbot, H. Keipp ^{[1
]}

Keitel, Wendy ^{[2
]}

Cate, Thomas R. ^{[2
]}

Treanor, John ^{[3
]}

Campbell, James ^{[4
]}

Bradye, Rebecca C. ^{[5
]}

Graham, Irene ^{[6
]}

Dekker, Cornelia L. ^{[7
]}

Ho, Dora ^{[7
]}

Winokur, Patricia ^{[8
,9
]}

Walter, Emmanuel ^{[10
]}

Bennet, Jillian ^{[11
]}

Formica, Neil ^{[11
]}

Hartel, Gunter ^{[11
]}

Skeljo, Maryanne ^{[11
]}

Edwards, Kathryn M. ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med & Pediat, Med Ctr, Nashville, TN 37232 USA

[2] Baylor Coll Med, Houston, TX 77030 USA

[3] Univ Rochester, Rochester, NY 14642 USA

[4] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[5] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA

[6] St Louis Univ, Hlth Sci Ctr, St Louis, MO 63110 USA

[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[8] Univ Iowa, Iowa City, IA USA

[9] Iowa City VAMC, Iowa City, IA USA

[10] Duke Univ, Durham, NC USA

[11] CSL Ltd, Parkville, VIC 3052, Australia

来源：

VACCINE | 2008年 / 26卷 / 32期

关键词：

influenza; vaccine; immunogenicity;

D O I：

10.1016/j.vaccine.2008.05.024

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer >= 40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4057 / 4061

页数：5

共 10 条

[1] Serum antibody responses after intradermal vaccination against influenza [J].

Belshe, RB ;

Newman, FK ;

Cannon, J ;

Duane, C ;

Treanor, J ;

Van Hoecke, C ;

Howe, BJ ;

Dubin, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (22) :2286-2294

[2] Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults [J].

Belshe, Robert B. ;

Newman, Frances K. ;

Wilkins, Ken ;

Graham, Irene L. ;

Babusis, Elizabeth ;

Ewell, Marian ;

Frey, Sharon E. .

VACCINE, 2007, 25 (37-38) :6755-6763

[3]

EDSALL G, 1972, J AMER MED ASSOC, V220, P137

[4]

Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1

[5]

*FOOD DRUG ADM CFB, 2006, GUID IND CLIN DAT NE

[6] Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults [J].

Frey, S ;

Poland, G ;

Percell, S ;

Podda, A .

VACCINE, 2003, 21 (27-30) :4234-4237

[7] Severe serum sickness following pneumococcal vaccination in an AIDS patient [J].

Hengge, UR ;

Scharf, RE ;

Kroon, FP ;

Pfeffer, K .

INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (03) :210-211

[8] Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004 [J].

Mitchell, DK ;

Ruben, FL ;

Gravenstein, S .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (10) :925-927

[9] Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States [J].

Treanor, John J. ;

Campbell, James D. ;

Brady, Rebecca C. ;

Keitel, Wendy A. ;

Drame, Mamadou ;

Jain, Varsha K. ;

Innis, Bruce L. .

HUMAN VACCINES, 2005, 1 (06) :239-244

[10]

2005, MMWR, V54, P749

← 1 →